The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and ...

Patients with severe asthma initiated dupilumab and tezepelumab treatment more often than other biologics between 2022 and ...

Among patients with asthma and obesity, about a quarter of encounters include obesity management, according to a poster at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy ...